1. Insights into Insulin Treatment Challenges: Real-World Evidence and Clinical Trial Data

3. Introduction/Background

4. Timely* Application of Insulin Therapy in T2DM

5. Dangers of Delayed Insulin Initiation

6. Patient Attitudes Toward Insulin: Fears and Misperceptions

7. Insulin, Clinical Inertia, and the Burden of Time Constraints

8. Delays in Therapeutic Intensification

9. Clinical Impact of T2DM

10. Insulin Therapy and the Severely Insulin-Resistant Patient[a,b]

11. Issues With Adherence and Persistence

12. Medication Errors May Be Associated With Greater Insulin Use

13. Complexity-of-Regimen Issues

14. U-500R: Treating the Severely Insulin-Resistant Patient With Long-Standing T2DM

15. What Is Clinical Inertia?

16. DAWN2 Results: Deficiencies in Communication and Education

17. MOSAIc Study: Associations Among Patient-Physician Interactions, T2DM-Related Distress, Insulin Adherence, and HbA1c

18. MOSAIc Study: Key Findings

19. Discrepancies Between Patients’ and Providers’ Perspectives on Medication Nonadherence: Qualitative Meta-Synthesis

20. U-500R Thrice Daily vs Twice Daily: Actual and CFB TDD Values

21. U-500R Thrice Daily vs Twice Daily: Body Weight CFB

22. EDITION 3: Comparison of IGlar 300 U/mL vs IGlar 100 U/mL in Insulin-Naive Patients

23. BEGIN LOW VOLUME: IDeg 200 U/mL Once Daily Compared With IGlar

24. Insulin Initiation and Titration Suggestions for T2DM: Canadian Diabetes Association

25. Results From the AUTONOMY Study

26. Autonomy, AUTONOMY, and Adherence

27. Conclusions

28. Abbreviations